Press Releases
Philip J. Bergman, DVM, PhD, DACVIM (Oncology) Joins ELIAS Animal Health Scientific Advisory Board
LENEXA, Kan., April 10, 2025 -- ELIAS Animal Health, a leading innovator in cancer immunotherapies for veterinary medicine, today announced that Dr. Philip J. Bergman, DVM, PhD, DACVIM (Oncology), has joined its Scientific Advisory Board. Philip J. Bergman, DVM, PhD, DACVIM (Oncology) Dr. Bergman brings extensive experience in veterinary oncology, immunotherapy, and translational medicine, with a distinguished career in clinical research and cancer treatment advancements. He has played a pivotal role in pioneering novel cancer therapies for companion animals, including ONCEPT® (a registered trademark of Boehringer Ingelheim Animal Health) which is a fully licensed canine melanoma vaccine, and [...]
ELIAS Animal Health Receives Full Approval from USDA for the ELIAS Cancer Immunotherapy (ECI®), First-In-Class Treatment for Canine Osteosarcoma
LENEXA, Kan., Mar. 19, 2025 -- ELIAS Animal Health, a leading companion animal cancer therapeutics company, today announced its adoptive cell therapy, ELIAS Cancer Immunotherapy (ECI®), has received full approval from the U.S. Department of Agriculture (USDA) Center for Veterinary Biologics (CVB). Cancer is the leading cause of death in dogs over the age of two and represents a significant unmet medical need in veterinary medicine, with an estimated 6 million dogs diagnosed with cancer each year. ECI®, the first autologous prescription product to receive USDA-CVB approval, is indicated for the treatment of canine osteosarcoma, a deadly form of bone [...]
ELIAS Animal Health Conducting Limb-Sparing Canine Osteosarcoma Clinical Study with Grant from Morris Animal Foundation
LENEXA, Kan., July 31, 2024 /PRNewswire/ -- ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, has initiated a new study evaluating the company’s adoptive T cell therapy—the ELIAS Cancer Immunotherapy (ECI®)—in combination with a novel adjuvant as a limb-sparing treatment for large-breed dogs suffering from appendicular osteosarcoma. The study, which is funded by a grant from Morris Animal Foundation, will be conducted in collaboration with Dr. Jeffrey Bryan and Dr. Megan Mickelson at the University of Missouri. “For dogs with appendicular osteosarcoma, amputation of the affected limb followed by chemotherapy is the [...]